Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE.
ACTOPLUS MET vs PIOGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), modulating transcription of genes involved in glucose and lipid metabolism, increasing insulin sensitivity in adipose tissue, muscle, and liver.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
15-30 mg orally once daily; maximum dose 45 mg/day.
None Documented
None Documented
Clinical Note
moderatePioglitazone + Gatifloxacin
"Pioglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePioglitazone + Rosoxacin
"Pioglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePioglitazone + Levofloxacin
"Pioglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderatePioglitazone + Trovafloxacin
"Pioglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life is 3-7 hours in healthy adults, but extends to 16-24 hours in patients with hepatic impairment due to reduced clearance. Steady-state is achieved after 4-6 days of dosing.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Primarily hepatic metabolism via CYP2C8 and CYP3A4; approximately 15-30% excreted in urine as metabolites, with the remainder in feces (~70%) via biliary elimination. Renal excretion of unchanged drug is negligible (<1%).
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione